Startups

Cochlear Limited

Cochlear Limited is an Australian medical-technology company that develops, manufactures and commercializes implantable hearing systems. Its products include Nucleus cochlear implants and external sound processors, alongside Baha and Osia bone-conduction systems, connected applications and services supporting recipients over the life of their implants. Headquartered in Sydney, the company began operations in 1981 and is listed on the Australian Securities Exchange. It conducts hearing research and develops technology with clinical and industry partners; its investment in OculAudio Corti AS supported research into an eyeglass-based microphone accessory for cochlear implant users.

Founded 1981

Team

Alison DeansChair

Anthony BishopPresident, Europe, Middle East and Africa

Brian KaplanSenior Vice President, Global Clinical Strategy and Innovation

Bruce RobinsonNon-executive Director

Caroline ClarkeNon-executive Director

Christine McLoughlinNon-executive Director

Dean PhizackleaSenior Vice President, Global Strategic Marketing

Dig HowittCEO, President and Managing Director

Greg BodkinSenior Vice President, Global Supply Chain

Jan JanssenChief Technology Officer

Karen O’DriscollChief Information Officer

Karen PenroseNon-executive Director

Lisa AubertPresident, North America

Michael DaniellNon-executive Director

Michael del PradoNon-executive Director

Richard FreudensteinNon-executive Director

Rob McGroryGroup General Counsel and Company Secretary

Sabina SopovChief People Officer, Global People and Culture

Sarah ThomChief Financial Officer

Stu SayersPresident, Asia Pacific and Latin America

Investments

$—2023-03-07

OculAudio Corti AS

Cochlear Limited

team@apexlogos.ai2 days ago
Cochlear Limited is an operating medical-technology company acting as a corporate strategic investor. Sarsia’s March 7, 2023 announcement expressly states that Cochlear made its first investment in OculAudio Corti AS (Norwegian registry 930839590); the R&D program was jointly funded. The announcement does not disclose equity ticket, total program budget, instrument, investment lead status or round stage. OculAudio Corti AS is distinct from OculAudio AS and Danish Corti AI; no Sarsia fund allocation or parent/subsidiary ownership is inferred. The native financing round is 46749. Source: https://sarsia.com/news/oculaudio-signs-deal-with-hearing-implant-giant . Current public corporate leadership directory covers nine directors and twelve executives, with Dig Howitt overlapping, totaling twenty unique named leaders. Corporate committees are responsibilities of these directors, not separately invented employment positions. Sources: https://www.cochlear.com/us/en/corporate/investors/corporate-information/board-of-directors ; https://www.cochlear.com/us/en/corporate/investors/corporate-information/executive-team .